Q-omics provides the consensus-scored RPL6P30 profile across patient tissues and cancer cell-line models. RPL6P30 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL6P30 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RPL6P30 RNA expression shows 5,951 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight ACC, KICH, and OV as cancer lineages where RPL6P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL6P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL6P30 survival associations across molecular data types. RPL6P30 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL6P30 RNA expression–survival associations across cancer types. High RPL6P30 expression shows unfavorable associations in ACC, UCEC and LIHC, but favorable associations in READ, BRCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL6P30 RNA expression.
This table summarizes RPL6P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RPL6P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL6P30 shows lower tumor expression in READ and higher tumor expression in KICH, COAD, LIHC, CHOL and PRAD. The KICH box plot shows higher RPL6P30 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p < 0.001).
This table shows molecular features associated with RPL6P30 in patient tissues and cancer cell lines. In patient samples, RPL6P30 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
